134 related articles for article (PubMed ID: 34018844)
1. Characterization of
Carloni LE; Wechselberger R; De Vijlder T
Nucleic Acid Ther; 2021 Oct; 31(5):341-350. PubMed ID: 34018844
[TBL] [Abstract][Full Text] [Related]
2. Oligonucleotide n3'-->p5' phosphoramidates and thio-phoshoramidates as potential therapeutic agents.
Gryaznov SM
Chem Biodivers; 2010 Mar; 7(3):477-93. PubMed ID: 20232321
[TBL] [Abstract][Full Text] [Related]
3. Oligonucleotide N3'-->P5' phosphoramidates as efficient telomerase inhibitors.
Herbert BS; Pongracz K; Shay JW; Gryaznov SM
Oncogene; 2002 Jan; 21(4):638-42. PubMed ID: 11850790
[TBL] [Abstract][Full Text] [Related]
4. Imetelstat (a telomerase antagonist) exerts off‑target effects on the cytoskeleton.
Mender I; Senturk S; Ozgunes N; Akcali KC; Kletsas D; Gryaznov S; Can A; Shay JW; Dikmen ZG
Int J Oncol; 2013 May; 42(5):1709-15. PubMed ID: 23545855
[TBL] [Abstract][Full Text] [Related]
5. Telomerase inhibitor Imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cells.
Burchett KM; Yan Y; Ouellette MM
PLoS One; 2014; 9(1):e85155. PubMed ID: 24409321
[TBL] [Abstract][Full Text] [Related]
6. Antiadhesive effects of GRN163L--an oligonucleotide N3'->P5' thio-phosphoramidate targeting telomerase.
Jackson SR; Zhu CH; Paulson V; Watkins L; Dikmen ZG; Gryaznov SM; Wright WE; Shay JW
Cancer Res; 2007 Feb; 67(3):1121-9. PubMed ID: 17283146
[TBL] [Abstract][Full Text] [Related]
7. Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells.
Akiyama M; Hideshima T; Shammas MA; Hayashi T; Hamasaki M; Tai YT; Richardson P; Gryaznov S; Munshi NC; Anderson KC
Cancer Res; 2003 Oct; 63(19):6187-94. PubMed ID: 14559802
[TBL] [Abstract][Full Text] [Related]
8. Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition.
Herbert BS; Gellert GC; Hochreiter A; Pongracz K; Wright WE; Zielinska D; Chin AC; Harley CB; Shay JW; Gryaznov SM
Oncogene; 2005 Aug; 24(33):5262-8. PubMed ID: 15940257
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the In Vitro Inhibitory Potential of the Oligonucleotide Imetelstat on Human Cytochrome P450 Enzymes with Predictions of In Vivo Drug-Drug Interactions.
Kazmi F; Sensenhauser C; Greway T
Drug Metab Dispos; 2019 Jan; 47(1):9-14. PubMed ID: 30389730
[TBL] [Abstract][Full Text] [Related]
10. Oligonucleotides Targeting Telomeres and Telomerase in Cancer.
Schrank Z; Khan N; Osude C; Singh S; Miller RJ; Merrick C; Mabel A; Kuckovic A; Puri N
Molecules; 2018 Sep; 23(9):. PubMed ID: 30189661
[TBL] [Abstract][Full Text] [Related]
11. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.
Frink RE; Peyton M; Schiller JH; Gazdar AF; Shay JW; Minna JD
Oncotarget; 2016 May; 7(22):31639-51. PubMed ID: 27192120
[TBL] [Abstract][Full Text] [Related]
12. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor.
Dikmen ZG; Gellert GC; Jackson S; Gryaznov S; Tressler R; Dogan P; Wright WE; Shay JW
Cancer Res; 2005 Sep; 65(17):7866-73. PubMed ID: 16140956
[TBL] [Abstract][Full Text] [Related]
13. Oligonucleotide N3' --> P5' thio-phosphoramidate telomerase template antagonists as potential anticancer agents.
Gryaznov S; Asai A; Oshima Y; Yamamoto Y; Pongracz K; Pruzan R; Wunder E; Piatyszek M; Li S; Chin A; Harley C; Akinaga S; Yamashita Y
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):577-81. PubMed ID: 14565232
[TBL] [Abstract][Full Text] [Related]
14. Short-term treatment with imetelstat sensitizes hematopoietic malignant cells to a genotoxic agent via suppression of the telomerase-mediated DNA repair process.
Hidaka D; Onozawa M; Miyashita N; Yokoyama S; Nakagawa M; Hashimoto D; Teshima T
Leuk Lymphoma; 2020 Nov; 61(11):2722-2732. PubMed ID: 32571117
[TBL] [Abstract][Full Text] [Related]
15. Stabilization of Telomere G-Quadruplexes Interferes with Human Herpesvirus 6A Chromosomal Integration.
Gilbert-Girard S; Gravel A; Artusi S; Richter SN; Wallaschek N; Kaufer BB; Flamand L
J Virol; 2017 Jul; 91(14):. PubMed ID: 28468887
[TBL] [Abstract][Full Text] [Related]
16. Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor.
Hu Y; Bobb D; Lu Y; He J; Dome JS
Cancer Genet; 2014 Sep; 207(9):403-11. PubMed ID: 25441685
[TBL] [Abstract][Full Text] [Related]
17. Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes.
Shawi M; Chu TW; Martinez-Marignac V; Yu Y; Gryaznov SM; Johnston JB; Lees-Miller SP; Assouline SE; Autexier C; Aloyz R
PLoS One; 2013; 8(7):e70428. PubMed ID: 23922990
[TBL] [Abstract][Full Text] [Related]
18. Treating Cancer by Targeting Telomeres and Telomerase.
Ivancich M; Schrank Z; Wojdyla L; Leviskas B; Kuckovic A; Sanjali A; Puri N
Antioxidants (Basel); 2017 Feb; 6(1):. PubMed ID: 28218725
[TBL] [Abstract][Full Text] [Related]
19. Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks.
Wu X; Smavadati S; Nordfjäll K; Karlsson K; Qvarnström F; Simonsson M; Bergqvist M; Gryaznov S; Ekman S; Paulsson-Karlsson Y
Biochim Biophys Acta; 2012 Dec; 1823(12):2130-5. PubMed ID: 22906540
[TBL] [Abstract][Full Text] [Related]
20. Specific binding of telomeric G-quadruplexes by hydrosoluble perylene derivatives inhibits repeat addition processivity of human telomerase.
D'Ambrosio D; Reichenbach P; Micheli E; Alvino A; Franceschin M; Savino M; Lingner J
Biochimie; 2012 Mar; 94(3):854-63. PubMed ID: 22182489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
